Cannabis (marijuana and hashish) constitutes the highest prevalence for psychotropic drug use worldwide, with an estimated 200 million users annually (1). As a result, urine drug testing (UDT) for cannabis use is very common. The testing is traditionally performed in a two-step process with an immunoassay for screening, followed by the confirmatory analysis of the ‘presumptive positive’ samples. Testing for cannabis is often part of workplace drug testing programs, doping analysis and roadside drug testing, where both immunoassay and confirmatory testing results are managed by trained professionals using working guidelines and validated procedures. In addition, point-of-care testing is performed in primary health-care settings, prisons, psychiatric wards and drug rehabilitation units (inpatient or outpatient) and sometimes in institutions where personnel in charge of UDT are less familiar with the fundamental principles and challenges of drug testing. Thus, due to the lack of certified training, standard procedures and documentation, interpretation of UDT results may become subjective and prone to error.

中文翻译：

---

应用数学模型来预测尿液药物检测新大麻的使用：是时候向前迈进了

大麻（大麻和大麻）是全世界精神药物使用率最高的，估计每年有 2 亿使用者（1）。因此，用于大麻使用的尿液药物测试 (UDT) 非常普遍。测试传统上分两步进行，先进行免疫测定进行筛查，然后对“推定阳性”样本进行验证性分析。大麻检测通常是工作场所药物检测计划、兴奋剂分析和路边药物检测的一部分，其中免疫测定和确认检测结果均由训练有素的专业人员使用工作指南和经过验证的程序进行管理。此外，在初级卫生保健机构、监狱、精神科病房和戒毒单位（住院或门诊），有时在负责 UDT 的人员不太熟悉基本原则和挑战的机构中进行即时检测药物测试。因此，由于缺乏经过认证的培训，